U. S. Food and Drug Administration. Drug Safety and Availability – FDA Drug Safety Communication: Ongoing safety review of Parkinson’s drug Mirapex (pramipexole) and possible risk of heart failure [Internet]. [citado 17 de dezembro de 2012]. Recuperado de: http://www.fda.gov/Drugs/DrugSafety/ucm319779.htm.

Drugdex System [Internet]. Estados Unidos: Thomson MICROMEDEX; Recuperado de: http://www.thomsonhc.com/.

Boehringer Ingelheim International GmbH. MIRAPEX® (pramipexole dihydrochloride) [Internet]. Disponível em: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020667s027lbl.pdf.

Boehringer Ingelheim do Brasil Quím. e Farm. Ltda. Dicloridrato de Pramipexol/Sifrol [Internet]. [citado 31 de janeiro de 2013]. Recuperado de: http://www.boehringeringelheim.com.br/arquivos/SifrolER.pdf.

Renoux C, Dell’Aniello S, Brophy JM, Suissa S. Dopamine agonist use and the risk of heart failure. Pharmacoepidemiology and drug safety [Internet]. 2012 [citado 4 de janeiro de 2013]; Recuperado de: http://onlinelibrary.wiley.com/doi/10.1002/pds.2267/full.